A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck - Wikidata - wikimedia - TriplyDB

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

http://www.wikidata.org/entity/Q34083131

about

Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)HER2 as a therapeutic target in head and neck squamous cell carcinoma Toward the use of precision medicine for the treatment of head and neck squamous cell carcinoma Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo miR-124 Regulates the Epithelial-Restricted with Serine Box/Epidermal Growth Factor Receptor Signaling Axis in Head and Neck Squamous Cell Carcinoma.Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.Afatinib reverses multidrug resistance in ovarian cancer via dually inhibiting ATP binding cassette subfamily B member 1.A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Pharmacotherapy of head and neck cancer.Afatinib in squamous cell carcinoma of the head and neck.Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma Visualization of early prostatic adenocarcinoma as a stem cell disease Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection.Personalized Medicine Approach for an Exceptional Response to Multiple-recurrent and Metastatic HER2-positive Oropharyngeal Squamous Cell Carcinoma.Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma.EGFR-targeted therapies in the post-genomic era.Emerging drugs for head and neck cancer.Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer.Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.Phase I open-label study of afatinib plus vinorelbine in patients with solid tumours overexpressing EGFR and/or HER2.Leveraging Genomics for Head and Neck Cancer Treatment.Effects of neratinib and combination with irradiation and chemotherapy in head and neck cancer cells.Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

P2860

Q26750719-6B141736-6736-4052-8CE9-30058065F980 Q26765429-FD0AFD11-5FBD-4C5E-9674-D28C3EF8C1CB Q27026178-BD29F277-1442-4111-9EFD-C9B1850F14BE Q28074691-BACDD8B3-A770-4323-9BE3-E52CE2B63D1C Q33650470-1E7D83A2-EB6F-453B-ABFB-A09412248699 Q33653707-A1F5FC6F-044D-436A-A5D4-28DC87111C70 Q33839177-3C3CF4DC-0299-493E-8EC3-35EE05C8C8F9 Q34896542-FFC72CF9-D8B0-478A-BDD6-BC53E7EC3E9D Q35807946-049B1163-EBAB-4279-A7A4-91DAC6F1E48B Q35822882-14221919-ED81-4C97-B1E6-3341BB68ED32 Q36132797-780D99C4-F53C-48E2-89F8-5D884BBC3C39 Q36371601-5C359116-7BE8-439D-8B51-8BBC9BFBCD5F Q36383018-6F95A295-2D91-4A34-B246-B63979E80A8F Q36413392-4EDDFFBC-1949-4C47-AC7B-C393408EAF86 Q36447729-C091F360-9DB1-4680-8330-CD842110A593 Q36766842-8DA43C00-2701-4D96-A1E6-86D2BAF36BE1 Q37146157-AD820CE3-3BE8-4A59-8852-7051B244DBC0 Q38514601-BAE08FF8-5523-4446-B955-DFE1489A814B Q38619293-FB01A564-550E-47FA-B45B-90165FE3633B Q38829891-7C1AF064-7986-41D4-A149-379F3EB380AD Q38838071-F85BF753-B375-4FCA-9F20-1040CC4FA45A Q38851114-57DFBA11-B0FB-40B2-8C97-A402E7F3280C Q38892486-D62CF578-2658-42D9-BC9F-BCC944391218 Q38971558-BAB0E3AA-7A7B-4C38-82B9-0130DC3D08A1 Q39187965-2657770F-F78E-435F-9413-4D180A04C7A2 Q39193035-85188BD8-1672-4AD4-A0BF-AFC2AB483D42 Q40970957-31F0F0FA-C5B5-4103-AC42-6A05FBD37C42 Q41851423-E28D74E2-F197-4928-BA72-257479D6E876 Q42625287-3DE4CDC9-4215-4662-AE4D-D458DB737456 Q44846795-D6207035-A07F-4FD0-B91C-CF0EF08D61AC Q45408645-C0C0659C-5AE5-4BA7-B7DF-EA55B42D3202 Q45871491-FA34C079-08E3-4212-8419-3750237D65D9 Q45874449-F088CE17-4919-44F1-8B3F-923B4E11A291 Q46738588-0CA17759-4D92-4579-BAB3-EF9CCF168254 Q47722276-B4D6A8DB-6068-409F-8188-816479834046 Q49220207-B0B46EA8-2C50-41A4-99EA-3C5460DB541E Q50026716-7CAD9790-2003-427E-8D71-F2CBD3C505D2 Q50116331-5ED94265-43C6-40B2-BD4D-B8EC235A431B Q51603922-581C92F8-9C13-4B32-B7FD-9CC91FA6DF26 Q52617485-0E124FD0-F761-4C5F-B962-FF35523EB027

P2860

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

http://www.wikidata.org/entity/Q34083131

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

A randomized, phase II study o ...... carcinoma of the head and neck

@ast

A randomized, phase II study o ...... carcinoma of the head and neck

@en

A randomized, phase II study o ...... carcinoma of the head and neck

@nl

type

label

A randomized, phase II study o ...... carcinoma of the head and neck

@ast

A randomized, phase II study o ...... carcinoma of the head and neck

@en

A randomized, phase II study o ...... carcinoma of the head and neck

@nl

prefLabel

A randomized, phase II study o ...... carcinoma of the head and neck

@ast

A randomized, phase II study o ...... carcinoma of the head and neck

@en

A randomized, phase II study o ...... carcinoma of the head and neck

@nl

P1433

Q34083131-C3633E05-DCBA-423C-B057-AA6A528B5660

P1476

Q34083131-061852AE-3F67-4D11-8411-237F83BD58F7

P2093

Q34083131-0A81678C-5CA1-4F52-A3AF-6174E8135000

Q34083131-236CB081-A5C9-42AA-B131-E363E2DA7EFC

Q34083131-3329A86B-33F9-47ED-9D75-0A875E4E73CB

Q34083131-57FAC152-B689-4F66-BB3D-69D64E2154AD

Q34083131-69B778F6-3E80-4C00-A1C8-0C7944A71672

Q34083131-712C9474-1DF3-4116-8ACE-BDE28F07D7AD

Q34083131-91E84CC0-5ACB-4C5F-9D93-8CC044FAB898

Q34083131-AFF78A4A-E0C2-4442-9F24-35E6E7FA4006

Q34083131-B49ED9B7-67D8-467D-8CE0-F316A608E051

Q34083131-ECE6043F-B4ED-490E-A35A-D82595431552

P2860

Q34083131-01EA759B-5E65-4D89-9904-B4D711D7D5C2

Q34083131-0CE1759C-B353-4CF9-B299-A0F336CE4167

Q34083131-22F20AA9-5CAF-4105-9532-F7E9CD33772F

Q34083131-253CC6C0-DF3B-4ADB-AB5B-AD7BC8FCC5F1

Q34083131-3595CF28-DE68-4FF3-9786-EB2B170134E3

Q34083131-37D4FCBA-8693-491E-8950-9BFFB1C316AD

Q34083131-53AD7AB1-3FE6-4BBA-98B1-A487080B8035

Q34083131-7D0E1CC8-4AEF-433B-83DC-16247A73B0B6

Q34083131-92453D80-0CBA-49AD-8A94-181BBC3058E3

Q34083131-A263831D-A383-49E3-BCA9-BE2858B942A2

P304

Q34083131-11B6FD17-4E2E-4EF6-A1C8-2DB929F9C0D8

P31

Q34083131-5E3EC100-F170-46E1-9498-D71147375055

P356

Q34083131-F65AD891-F9AC-48E1-AADD-2EFFD47AEE09

P433

Q34083131-34BBDA30-3CE4-404B-84EA-3E531F34BC66

P478

Q34083131-A3E4E89A-CFEB-45EE-8D1A-F76E752B84AB

P577

Q34083131-C8FA166C-DFCF-4FB2-BDB8-F827D06A9F84

P5875

Q34083131-FC1A1C0F-9320-4945-818F-1E18E1429A4D

P698

Q34083131-8B0344E3-68DF-4236-AADC-5E98DEAA0E06

P921

Q34083131-8AAD12C9-A604-43B5-9FBF-4092C51711EB

P932

Q34083131-18F0DD33-F74D-4BFF-9695-5A45E6461C18

P356

P1433

Annals of Oncology

P1476

A randomized, phase II study o ...... carcinoma of the head and neck

@en

P2093

A Blackman

http://www.w3.org/2001/XMLSchema#string

D Cupissol

http://www.w3.org/2001/XMLSchema#string

E E W Cohen

http://www.w3.org/2001/XMLSchema#string

E Ehrnrooth

http://www.w3.org/2001/XMLSchema#string

J Fayette

http://www.w3.org/2001/XMLSchema#string

J M Del Campo

http://www.w3.org/2001/XMLSchema#string

M Degardin

http://www.w3.org/2001/XMLSchema#string

P M Clement

http://www.w3.org/2001/XMLSchema#string

R Hitt

http://www.w3.org/2001/XMLSchema#string

T Y Seiwert

http://www.w3.org/2001/XMLSchema#string

P2860

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

The mutational landscape of head and neck squamous cell carcinoma

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.

P304

1813-1820

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU216

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263097193

http://www.w3.org/2001/XMLSchema#string

P698

24928832

http://www.w3.org/2001/XMLSchema#string

P921

P932

4143093

http://www.w3.org/2001/XMLSchema#string